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Abstract
Placebo effect is an alternative medical approach that doctors utilize in treating health issues. For years, people thought
that placebo pills were inert drugs or medically illegitimate measures that have psychological effects on the patient,
therefore alleviating the patient’s pain. However, in recent years, with the advent of technology, more studies are involving neurological aspects to the already-proven psychological aspects of the placebo effect. Yet there is still some
opposition and much to be proven better on this topic. What is very important is that although there is opposition,
there is growing recognition that the placebo effect may actually involve changes in brain chemistry, and that the placebo effect might be a fundamental part of good medical care that will one day be universally embraced by doctors and
patients as well.
Acronyms:
CBP		

Chronic Back Pain

CCK 		

Cholecystokinin

CR 		

Conditioned Response

CS 		

Conditioned Stimulus/Stimuli

NSAID 		

Nonsteroidal Anti-Inflammatory Drug

PAG		

Periaqueductal Gray

UCR		

Unconditioned Response

UCS 		

Unconditioned Stimulus/Stimuli

Introduction
Since the 18th century, people have believed that placebo pills
were inert drugs or medically unqualified measures that have
psychological effects on the patient, therefore easing the patient’s pain (Beecher 1955). Hence, the term placebo is a Latin
derivative for “I shall please” (Moerman 2002). Furthermore, in
recent years, many studies are associating neurological aspects
to the psychological effects of the placebo effect.
Today there is a range of treatment that people categorize as
placebo - as basic as administering a Band-Aid on a wound to
inserting needles into a patient receiving acupuncture. Because
such procedures do not contain much medical efficiency, their
pain-reducing results are termed ‘placebo effect.’ If these practices do not involve elements or substances that are responsible for altering a health condition then what is it about these
techniques that can make one pain free? Because placebo analgesia has proven to be one of the most successful models in
the research of the placebo effect, this review will explain the
long-known psychological influences of the placebo analgesia, as
well as the newer and unconcluded neurological influences of
the placebo analgesia.

Several psychological mechanisms contribute to the appearance, enhancement or duration of the placebo effects. Firstly,
Pavlov’s classical conditioning is a major contributor towards
the placebo effect, whereby a patient is trained to respond positively towards a placebo stimulus. Expectations also play a big
role - the patient’s anticipation of clinical improvement is partially responsible for the onset of the placebo effect. The overall
experience that the patient experiences influences the patient’s
expectations; doctor-patient relationship, the trial site, the appearance of the pill, and the way the treatment is given are all
experience related factors that impact one’s expectations.
How can it be that just by one merely having belief one can
experience less or no pain? The neural mechanisms whereby
placebo conditioning leads to placebo analgesia remain unclear.
Scientists are attempting to find better explanations for the
placebo effect by attributing it to neurological mechanisms of
the body. Ascending pain signals travel through one’s spinal cord,
then to the thalamus, and then to the sensory- processing regions of one’s cerebral cortex. In order for one not to experience pain due do to a pain provoking stimulus, there would have
to be changes in the sensory network of the brain or in the spinal cord. Recently, researchers are associating opiate analgesics
to the placebo effect.They are attempting to prove that placebo
treatment engages opioid systems which block pain in the spinal
cord. However, studies also show that there in fact is non-opioid
related analgesia. Nonetheless, the explanations remain unclear.
From the research done, it is evident that the placebo effect has
psychological aspects and that there is a difference in brain activity due to placebo treatment which is seemingly responsible
for placebo analgesia. Nonetheless, future research is required
in order to pinpoint the definite neural activity responsible for
the pain reduction.

Methods
In an effort to answer the question asked above, many published
articles, clinical trials, and research papers have been examined.
Primarily, Touro College’s library database as well as Google
Scholar were used to search for pertinent material. Original
research papers that were referenced were also studied. An
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attempt was made to determine if the placebo effect, as a result
of the placebo treatment, is psychologically and or neurologically fact or fiction.

Discussion
Psychological Aspects: Learning and Classical
Conditioning
People who suffer from pain, like a headache, and who usually
ingest aspirin, learn to associate the color, taste, and shape of
the pill with pain-decrease. After recurring associations, if such
people are given a placebo pill, such as a sugar pill resembling aspirin, they will feel less pain. Other stimuli, such as medical personnel features, hospitals, and therapeutic equipment can also
be associated with clinical improvements and therefore act as
conditioned stimuli that impact healing effects (Benedetti, et. al.
2010). A 1960s’ experiment found that a scopolamine injection,
a medication used to treat motion sickness and other types of
nausea, affected motor changes in a rat. Furthermore, identical
motor changes also transpired after a placebo injection made
of saline solution was administered after the scopolamine injection (Herrnstein 1962). Corresponding occurrences exist in
humans too. Notably, if a placebo pill or procedure is given after
two preceding administrations of an effective painkiller or practice, the placebo analgesic response is much larger (Amanzio,
Benedetti, 1999). That effect emphasizes that the placebo effect
is definitely a learning phenomenon.
Like other profound scientific developments, classical conditioning was discovered accidentally. In the 1890s, Russian physiologist Ivan Pavlov was observing dogs salivate in response to being
fed. He then noticed that the dogs began salivating whenever
he arrived in the room they were in, while he did not always
have food with him (McLeod 2007). From this incident, Pavlov
believed that some responses are innate, they don’t need to
be learned. In example, dogs do not learn to salivate whenever
they see food as this reflex is inherent. In psychological terms,
an unconditioned stimulus leads to an unconditioned response.
Furthermore, over time the dogs began salivating as soon as they
saw anything that they associated with their food. Therefore,
they would salivate in the presence of a lab assistant even when
he did not come with food (Windholz 1995). In psychological
terms, the phenomenon is due because when an unconditioned
stimulus is paired with a neutral stimulus, the latter becomes a
conditioned stimulus that propels a conditioned response comparable to the unconditioned response. Pavlov furthered his
research by experimenting with a bell; the dog was conditioned
to salivate when a bell rang as he associated it with the food.
Numerous clinical trials attribute the positive placebo treatment effects to Pavlov’s classical conditioning. Just as a dog salivated in response to a food-associated person or object, people
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can experience a reduction in pain due to a painkiller-associated
placebo procedure or drug. Indeed, a 1970s’ experiment proves
that placebo effects are in large due to classical conditioning;
saccharin, a flavored drinking solution, was paired with cyclophosphamide, an immunosuppressive drug, and given to rats.
After, the rats were immunized with sheep red blood cells.
On the seventh day, the rats that had been again exposed to
saccharin at the time of antigenic stimulation had a lower concentration of hemagglutinating antibodies in comparison with
non-conditioned animals given saccharin, conditioned animals
that were not re-exposed to saccharin, and a placebo group.
Hence, the experiment proves that after associative learning,
simply a liquid has the ability to mimic the effects of an active
drug and thus legitimizes the placebo effect (Ader, Cohen 1975).
In response to people who argue that such conditioning is
not possible to exist amongst human beings, an analogous trial
provides substantial evidence that behavioral conditioning of
immunosuppression is in fact promising in humans. Recurrent
associations between cyclosporine A - an immunosuppressant
drug - and a flavored drink incited conditioned immunosuppression in healthy male volunteers. However, more than one
associative learning trial was necessary in order to bring about
the fascinating results (Goebel, et al 2002).

Psychological Aspects: Expectancy
While Pavlovian conditioning serves as an unconscious influence towards placebo effects, expectancy serves as a conscious
one. The expectancy theory hypothesizes that one’s expectations impact ones future experience (Kirsch 1999). Therefore, if
one expects clinical improvement, his chances of improving are
that much greater. This theory is evident in the following 2010
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double-blind clinical trial: A painful laser stimulus was delivered
individually to twenty healthy participants before and after each
was given a 0 or 4 mg/kg cup of caffeine. Some participants were
told that their drink contained a painkiller, while the others
were told their drink was a placebo solution. After measuring
the reported pain and expectancy levels, it was clear that the
information that a painkiller was given enhanced the analgesic
effect of caffeine compared to caffeine given with no drug information (Bjørkedal, Flaten 2011). Moreover, those that were in
the active placebo condition group - were told they were given
a painkiller and they received caffeine – overall reported less
pain than the subjects in the caffeine condition group – were
not told they were given painkiller and they received caffeine.
This reiterates the expectancy theory, as the first group was
given two qualities (caffeine and drug information) that made
them expect an improvement, while the latter group was only
given one (caffeine).The expectancy of pain relief modulated the

variations of spontaneous pain, at the starting time and at two
more points thereafter (6 hours and 2 weeks). As reported,
there was no noteworthy difference between the two groups
in their pain intensity and in pain related brain activity. And both
groups reported more than a 50% pain decrease. Moreover,
when compared with an untreated chronic-back-pain-group at
similar intervals, the patch treated CBP group experienced a
considerably bigger decrease in back pain (Hashmi et al, 2012).

Figure 3

Figure 2

Variation of CBP pain with treatment type and treatment duration.
Treatment duration, but not type, significantly decreased CBP pain.
(Hashmi et al).
These findings support the expectancy theory, as the patients
who experienced a more encouraging experience by being
given a patch consequently felt less pain later on (fig. 3).

Subjects reported larger reductions in pain after 4mg/kg caffeine
(caffeine, active placebo) compared to after 0mg caffeine (control,
placebo). (Bjørkedal, Flaten 2011)
decreased pain experienced by the subjects (fig. 2).
From the above trial, it is evident that verbal gestures enhance
expectancy in patients. Additionally, the overall experience
that the patient experiences influences his/her expectancy of
clinical improvement and consequently his/her clinical results.
The doctor-patient relationship, the trial site, the appearance
of the pill, and the way the treatment is given are all included in one’s experience and can enhance the placebo effect. In
another study, the effectiveness of 5% Lidocaine patches was
compared with the effectiveness of placebo patches in treating
chronic back pain. In the randomized double-blind study, 15 patients received 5% Lidocaine patches and 15 received placebo
patches. Functional MRI was used to ascertain brain activity for

Another method to reinforce one’s expectation of clinical
improvement, is to educate the individual about the so-called
painkiller one is going to ingest. A random group of fifty university students agreed to either undergo placebo treatment
under the appearance of a new analgesic painkiller capsule or
to be put in the control group which did not receive placebo
treatment. While some participants were handed educational
handouts explaining the analgesic effect, others were not. The
subjects then received electrically-induced pain at varied intensities, and those that ingested the realistic looking drug capsules
reported analgesia. Furthermore, participants who also read the
handouts regarding analgesia reported an even higher decrease
in pain (Tang, Colagiuri 2013). This experiment highlights that
the appearance of the pill and the knowledge of analgesia both
contribute towards the patients expectancy and thus towards
his or her placebo analgesia.

Psychological Aspects: Conditioning vs.
Expectancy Theory
After much research, it is evident that both the conditioning
and expectancy theories are driving forces of placebo effects.
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However, can they coexist, and is one more potent than the
other? In response to the former, both psychological mechanisms can surely coincide. For example, a patient who receives
a sugar pill on its own after repetitively receiving the pill together with other analgesic drugs will imply both mechanisms; the
sugar pill has become the conditioned stimulus to invoke analgesia, and the fact that the patient received medicine prompts
him to expect a recovery.
Regarding which mechanism is more vital, Stewart-Williams
and Podd (2004) reviewed many clinical trials and concluded
similarly to what many others have suggested: each mechanism
plays a different part in the production of placebo effects.When
a doctor verbally encourages a patient, when an inert pill or
procedure resembles a legitimate pill or procedure, and when
other such characteristics mentioned previously exist when
a patient receives a placebo, he/she learns to expect an improvement, which is a conscious belief. When one’s conscious
is involved, he can experience subjective and or physiological
placebo effects. On the other hand, when placebos represent
CS, the patient can either unconsciously believe in a placebo
effect or the patient can consciously expect improvements in
his situation.The conscious expectations and the non-conscious
learning yields subjective and physiological (objective) placebo
effects. Whilst expectancy learning is always a conscious action,
conditioning can be conscious or not - depending on whether
expectancy coincides with the conditioning. Nonetheless, each
form of learning can produce subjective as well as physiological
outcomes.
Others describe the correlation between expectations and
conditioning differently. A study concluded that placebo responses are facilitated by expectation when conscious physiological processes - for example, pain - exist, notwithstanding,
a conditioning procedure may simultaneously be implemented
(Benedetti et. al, 2003). Sixty participants were divided into five
groups and induced with pain in their forearms once per day
for five days. Such ischemic pain increases over time rapidly, and
the pain becomes excruciating after approximately 13 minutes.
After the painful stimulus was implied, each participant stopped
a timer when the pain became unbearable, and thus the average
pain tolerance level for each group was recorded. As each group
was treated differently throughout the five days, the results of
each group greatly varied. Some were told analgesia suggestions
or hyperalgesia suggestion, some experienced conditioining
via ketorolac anti inflamatory analgesic, and some received a
combination. Evidently, verbally induced analgesia expectations
raised the pain tolerance; whereas, suggestions of hyperalgesia
eradicated pain tolerance. This testifies that not only are positive words empowering, negativity is impactful too. Moreover,
this highlights the detrimental effects of unencouraging words
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in the medical scene.When analgesia suggestions and conditioning were both implemented, the tolerance level rose higher. Yet,
when conditioning and hyperalgesia suggestions coincided, the
expectations outweighed the preconditioning effects of ketorolac, as the subjects’s overall pain tolerance decreased. The study
proves that analgesic placebo responses seem to be primarily
mediated by expectations, such as verbally induced expectations.
The study of the placebo phenomenon has important implications on non-placebo procedures. The equivalent psychological
factors that mediate the placebo effect are likely to be effective
when an individual is given an active substance or undergoes
an active procedure. Accordingly, a better understanding of
the psychological mechanisms essential to the placebo effect
is relevant in order to contribute these psychological factors
to non-placebo treatments as well. For example, by increasing
patients’ positive expectancies for the effects of an active drug
or procedure, it is conceivable that the drug or procedure will
yield stronger drug effects without the use of stronger doses.
There are numerous ways that physicians can achieve this: They
can inform patients about others for whom the treatment
proved successful, and doctors should update patients on the
clinical research that portrays the treatment as worthwhile.
Additionally, physicians should make people aware of the minor
side effects related with the treatment. Then, when people
come across any such symptoms in themselves (irrespective
of whether these symptoms are a result of the active drug),
they are likely to assume that the drug is working well. This will
possibly boost their expectations for a positive effect, which will
thereafter enhance the placebo element of the active treatment.
Using these strategies, physicians can probably achieve stronger
drug results without administering alternative stronger drugs or
greater doses. This would be a safer solution for the patient, as
he or she will not be exposed to unnecessary strong medication, and this will also decrease the costs of medical care. (Podd,
Stewart-Williams 2004)

Neurological Aspects
Placebos have no innate power to elicit given results. Yet, they
can produce the effects which are anticipated or sought. Placebo
pills and procedures do not act on the brain to bring about placebo effects; however, placebos can stimulate expectations and
CR which impact pain-reducing neural systems.What is responsible for the relation between the psychological mechanisms
and placebo analgesia?

Neurological Aspects: Opioids
The neurology of placebo was discovered when researchers
found that placebo analgesia is facilitated by endogenous opioids. They were prompted to make this hypothesis after they
observed that naloxone, the opioid antagonist, can oppose the
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effects of placebo analgesia (Levine et. al, 1978). Since then, further studies have emphasized that finding. Researchers examined the mechanisms fundamental to the activation of endogenous opioids in placebo analgesia (Benedetti, Amanzio 1999).
Once a day, for five days, ischemic arm pain was induced into
229 participants. The subjects were divided into twelve groups,
each treated differently. Each group received a combination of
two or more of these
treatments throughout the five-day-experiment duration: the
opioid agonist morphine hydrochloride, the non-opioid ketorolac (nonsteroidal anti-inflammatory drug; NSAID) tromethamine, no treatment, an open injection of saline, or open or
hidden opioid antagonist naloxone. The order of each group’s
treatment was made so that the treatment can serve as drug
conditioning, expectation cues, or both. When morphine was
administered, and when saline was openly injected and was
believed to be a morphine-like (expectation and or drug conditioning), participants experienced less pain. Any participant
who received naloxone after morphine (ketorolac was not
administered), whether open or hidden and whether used as
an expectation cue or not, experienced no difference in pain.
When ketorolac was issued, there was pain relief. Moreover,
when saline was issued, it mimicked the ketorolac effects. What
was even more fascinating about the results was that when naloxone was issued after ketorolac, pain was partially diminished.
This proves that naloxone only somewhat blocks analgesic effects; therefore, there must be non-opioid factors in addition to
opioid factors influencing placebo analgesia. The results of the
experiment prove that the opioid system is surely involved in
placebo analgesia, yet there are also other aspects sometimes
involved.
There is a lack of evidence proving how non-opioid pathways
serve in placebo analgesia. However, just as ketorolac is a
NSAID, placebos that mimic ketorolac or other NSAIDs’ activity, probably behave like such drugs. They act at peripheral
and also central places in the spinal cord, hindering the cyclo-oxygenase enzyme that is essential for the transformation
of arachidonic acid into prostaglandins and thus preventing a
painful experience.
Because studies prove the anti-opioid accomplishments of the
neuropeptide cholecystokinin (CCK), further studies were done
and demonstrated that the blockade of CCK receptors makes
the placebo analgesic response possible, thus suggesting that the
CCK role in placebo analgesia is quite impeding and that the
opioid system is important in order for placebo analgesia to
occur. This finding imparts that by irritating the anti-opioid action of CCK at the time of a placebo practice, the endogenous
opioid systems can be activated. (Benedetti, Amanzio 1997) In

a more recent study, forty participants were divided into four
groups in order for the effects of CCK type-2 receptors to
be examined (Benedetti et. al, 2010). Each participant was induced with ischemic arm pain like in previously mentioned experiments, and each group was treated differently. The results
portrayed that activation of CCK type-2 receptors, which was
achieved by means of administering the agonist pentagastrin,
abolished placebo analgesia even after morphine-conditioning
(placebo treatment) occurred. Evidently, CCK resembles naloxone. Furthermore, this study suggests that the equilibrium
between CCK elements and opioids is critical in placebo treatment. So, when patients do not respond as predicted to placebo
treatments, possibly CCK type-2 receptor hyperactivity exists
in the patient’s body-makeup.
What exactly is the endogenous opioid system? In general, the
endogenous opioid system is an inborn pain-relieving method.
It consists of dispersed neurons that produce three opioids: beta-endorphin, the met- and leu-enkephalins, and the dynorphins.
These opioids behave like neurotransmitters and neuromodulators at three main categories of receptors - mu (μ), Delta (δ),
and kappa (κ). Once attached to the receptors, they send signals
which in turn block pain, slow down breathing, and have an overall calming effect; therefore, the patient experiences analgesia.
In order to more fully comprehend how opioids modulate the
conduction of pain, one needs to understand the pathway by
which pain is transmitted - beginning from its origin until its place
of interpretation and perception in the brain. There are two
types of first order neurons in which pain is transmitted along:
In terms of nociceptive pain transmission, acute pain is transmitted mainly by A-delta afferent sensory nerve fibers, while
chronic pain is transmitted mainly by unmyelinated C sensory
afferent nerve fibers until it reaches the spinal cord. Because
these nerve fibers are unmyelinated, chronic pain is transmitted
slower than acute pain. Nociceptors, free nerve endings which
are found in numerous visceral and somatic tissues all over the
body, are stimulated by different sorts of noxious (harmful)
stimuli - such as chemical, thermal, and mechanical - and once
stimulated there is a release of leukotrienes, bradykinin, histamine, prostaglandins, potassium ions, and substance P. These
substances activate the nociceptors which results in the generation of an action potential down the first order neurons and
heading towards the spinal cord. When the fibers arrive at the
dorsal gray horn of the spinal cord, they release neurotransmitters - glutamate, substance P, and calcitonin gene related peptide
- and thus synapse with second order nerve fibers.The released
neurotransmitters incite the depolarization of the second order
neuron which crosses over to the opposite side of the spinal
cord, entering the contralateral spinothalamic tract and from
there ascends up the spinal cord and ultimately into the brain.
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Here, pain is modified via descending pathways and this results
in an individual experiencing pain.
Now, how do opioids hinder the descending pathways so that
an individual does not perceive pain? Opioid agonists bind to
μ -opioid receptors within the midbrain of the brainstem, on
inhibitory interneurons. The opioid agonist action at these neurons results in a lessening in the inhibitory effects on the nerve
fibers exiting the periaqueductal gray (PAG). Hence, they lead
to disinhibition of the descending nerves from the PAG. In turn,
there is an increase in their motion and in their communication
to the raphe nuclei. Moreover, there will be a disinhibition of
neurons in the raphe nuclei. There will be a general stimulation
of the descending nerve fibers which are descending through
the lateral funiculus in the spinal cord, and they eventually reach
the dorsal horn of the spinal cord. As this is the site in which the
original pain stimulus enters the spinal cord in its ascent to the
brain, here the nerve fibers influence the activity of the initial
pain stimulus.
Opioids impede afferent sensory nerve fibers, as well, that are
ascending the spinal cord traveling towards the brain. Opioids directly attach to presynaptic mu-opioid receptors and thus cause
an inhibition of pain transmission through the first order afferent sensory nerve fibers which enter the spinal cord. This leads
to a lessening in the discharge of substance P that is required
for the stimulation of second order neurons. Furthermore, opioids can directly attach to postsynaptic mu-opioid receptors on
different ascending nerve fibers, and this adds to the diminished
communication to the ventral posterolateral nucleus and consequently to the cerebral cortex. Additionally, opioids can indirectly inhibit second order ascending neurons in the spinal cord;
they modify the ejection of substance P and serotonin from the
stimulated descending nerve fibers from the raphe nuclei which
control endorphin containing neurons inside the dorsal horn.
The outcome of the impacts of opioids on the nerves found in
the dorsal horn is the pain transmission inhibition.
As one’s body does not produce enough natural opioids to
alleviate excruciating or prolonged pain, opioid drugs are manufactured. Comparable to their endogenous complements, opioid drugs - opiates - act at the same receptor sites, producing
analgesia as well.This wonder is possible, as the drugs mimic the
endogenous opioids’ chemical makeup. For this reason, patients
who experience much pain are prescribed with painkillers –as
they are opiates which mediate analgesia. When a placebo is
administered, the goal is that the endogenous opioid system
is activated as a result of the psychological influence on the
patient’s mind – the individual is convinced he or she received
an opiate, so his body responds respectively.
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Ethics of Placebo Treatment
As the physiology caused by placebo treatment is not conclusive, the placebo effect is not universally recommended. In fact,
many view placebo treatment as immoral. According to Nikola
Biller-Andorno (2004) of University of Goettingen, Germany,
placebo treatment is only permissible when used for therapeutic reasons and when no better proven alternative exists.
Additionally, the patient cannot be deceived, rather the doctor
must acknowledge the patient’s empowerment and autonomy.
If the physician fails to abide by these standards, rather than
practicing ethically he is practicing blunderingly. Because of such
guidelines, it is difficult to practice placebo treatment on sick
patients. Therefore, researchers are forced to set up trials in
order to examine placebo effects.

Ethnic
After much research, it is noticeable that the placebo effect has
become more effective. DiSalvo elaborated about the placebo
effect in a 2015 edition of the Forbes magazine. He wrote that
after reviewing a study of 84 clinical trials which were carried
out between the years 1990 and 2013, he concluded that the
placebo effect is getting stronger. However, he adds that this is
only true of trials in the United States. Possibly because America
is more advanced than many countries, the ability to conduct
placebo treatments is more feasible. More importantly, he adds
that America is the only country aside from New Zealand
that allows drug companies to sell their products directly to
consumers. This is blatant when one watches TV and sees the
numerous drug commercials. The advertising in itself can contribute towards the placebo effect by creating expectation cues.

Conclusion
After examining the articles and experiments regarding placebo treatments and effects, it is apparent that while placebo
treatment definitely has psychological influence on patients, the
neurological influence is unclear. Many are skeptical of placebo
effect all together. They argue that possibly the percentage of
patients that report improvement would regardless have improvement – that is to say, often pain reduces over time so even
without a placebo treatment one can be somewhat relieved
from pain. However, in many trials, there are ‘natural history’
groups which are used to compare their pain tolerance to the
placebo treated group’s pain tolerance. And these studies have
proven that the placebo treated group’s pain tolerance was better than the non-placebo treated group’s tolerance. This topic
is fascinating as it proves the power of the mind over matter.
Placebo management can trigger mechanisms that are equivalent to those triggered by drugs, which points out a parallel
between psychological and pharmaceutical effects. With further
research, placebo effect may become completely acceptable and
instead of administering drugs which often have harmful side
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effects or which are sometimes rejected by patients, placebo
treatments will serve as alternatives.
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